Skip to content
TrialMatch
Sign up
Recruiting

Decipher Lethal Prostate Cancer Biology - Urine Metabolomics

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer. In the meantime, with these new markers we may substantially reduce overtreatment of insignificant PC.

Condition
Significant Prostate Cancer
Tested
Multi-Carotenoids
Sponsor
National Taiwan University Hospital

Who can join

Age
30 to 100 years
Sex
Male only
Healthy volunteers
Not accepted

Inclusion 8

  • Minimum age: 30 years
  • Maximum age: 100 years
  • Eligible sex: Male
  • Study condition: Significant Prostate Cancer
  • Subjects who have planned to undergo prostate biopsy or have completed biopsy before 6 weeks.
  • Subjects who are aged between 30 and 100 years men.
  • For subjects who are prostate cancer patients for rebiopsy, the testosterone level should be within normal limit (testosterone \>1.5 ng/ml).
  • Subjects who understand the entire study procedures and consent to donate his spot urine (once for 50 ml) and agree with subsequent analyses of his clinical information including biopsy results, treatments and outcomes. (Note: Subjects will be told that the urine metabolomics results will not be revealed to them.)

Exclusion 10

  • Subjects who have other active cancers. However, subjects who have cancers that have been curatively treated and who are disease-free for 3 years or longer are allowed to be enrolled.
  • Subjects who have severe organ function impairment which may significantly alter general cell metabolism determined by the investigators, such as or Cre \> 3.0, HbA1c \> 9.0%, symptomatic heart failure, or other symptomatic metabolic diseases.
  • Subjects who are receiving or have received systemic therapy, such as chemotherapy, androgen deprivation therapy (ADT), immunotherapy, or targeted therapy within 3 months of the screening.
  • Subjects who have been treated with pelvic radiotherapy within 3 months of the screening.
  • Subjects who have significant infection or inflammation within 8 weeks of the biopsy.
  • Subjects who have pyuria (defined as \> 5 WBC/HPF) of urinalysis results within 4 weeks of the biopsy
  • Topical or oral prednisolone equivalent dosage larger 10 mg per day for 14 days or more.
  • The last dose of prednisolone is within 4 weeks of the biopsy.
  • Subjects who have a life expectancy less than 12 months.
  • Subjects who use MCS or found supplementation containing large amount of lycopene in recent 60 days or less. The definition of large amount of lycopene is more than 2 mg per day.

Where

1 site, 1 recruiting

Department of Urology, National Taiwan University Hospital

Taipei, Taiwan

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.